Alzheimer's Disease

The FDA has granted breakthrough therapy designation to gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, as an Alzheimer’s disease treatment.

NIH Director Francis S. Collins, MD, PhD, who has served under three U.S. presidents, will step down from the position by the end of the year, according to an agency press release.

Methylphenidate safely and effectively treated apathy in Alzheimer’s disease, according to results of a randomized placebo-controlled clinical trial published in JAMA Neurology.

Levetiracetam was well tolerated and appeared to improve performance on spatial memory and executive function tasks among patients with Alzheimer’s disease, according to results of a randomized clinical trial in JAMA Neurology.

Alzheimer’s disease remains a significant public health challenge, with as many as 5.8 million Americans having had the disease in 2020, according to estimates in a study published in Alzheimer’s & Dementia.

In conjunction with World Alzheimer’s Day, Healio Psychiatry has compiled a list of articles covering recent research developments related to Alzheimer’s disease.

Social support in the form of listening is linked to improved cognitive resilience, according to findings published in JAMA Neurology.

NIH’s National Institute on Aging announced a $55.6 million grant for Alzheimer’s disease research conducted by the University of Washington, Kaiser Permanente Washington and the University of California San Diego.

NIH’s National Institute on Aging announced $14.8 million in funding across 5 years for institutions in North Carolina and Texas that will join a network of research centers for Alzheimer’s disease and related dementias.

Black women had higher rates of Alzheimer’s disease and environmental exposure to fine particulate matter than white women, according to a prospective, population-based study in Journals of Gerontology: Series A.